2021
DOI: 10.1186/s13643-021-01764-9
|View full text |Cite
|
Sign up to set email alerts
|

Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials

Abstract: Background Although oral opioid agonist therapies (OATs), buprenorphine and methadone, are effective first-line treatments, OAT remains largely underutilized due to low retention rates and wide variation across programs. This rapid review therefore sought to summarize the retention rates reported by randomized controlled trials (RCTs) and controlled observational study designs that compared methadone to buprenorphine (or buprenorphine-naloxone). Methods … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
26
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 56 publications
(27 citation statements)
references
References 34 publications
0
26
0
1
Order By: Relevance
“…However, a systematic review of the published literature on XR-NTX (Jarvis, Holtyn, et al, 2018b) pointed out that premature discontinuation of treatment with XR-NTX is common, with retention rates ranging from 15% to 74% in prospective studies, and that less than 10% adhered to XR-NTX after 6 months in retrospective studies of medical records. A recent review identified that retention rates in OMT are equally variable, ranging from 20.0% to 83.8% (Klimas et al, 2021). Nevertheless, Jarvis, Holthyn et al (2018b) concluded that the high proportion of patients discontinuing treatment limits the clinical utility of XR-NTX.…”
Section: Introductionmentioning
confidence: 99%
“…However, a systematic review of the published literature on XR-NTX (Jarvis, Holtyn, et al, 2018b) pointed out that premature discontinuation of treatment with XR-NTX is common, with retention rates ranging from 15% to 74% in prospective studies, and that less than 10% adhered to XR-NTX after 6 months in retrospective studies of medical records. A recent review identified that retention rates in OMT are equally variable, ranging from 20.0% to 83.8% (Klimas et al, 2021). Nevertheless, Jarvis, Holthyn et al (2018b) concluded that the high proportion of patients discontinuing treatment limits the clinical utility of XR-NTX.…”
Section: Introductionmentioning
confidence: 99%
“…Treatment drop-out was defined as not presenting to receive buprenorphine for 60 consecutive days without subsequent re-engagement in treatment for the duration of the study period. While there are no universally accepted definitions for treatment interruptions and treatment drop-out, we chose 60 days in alignment with previous studies among people receiving medications for opioid use disorders that have defined treatment interruptions and/ or treatment drop-out based on consecutive non-attendance for time periods anywhere between 30 and 90 days [18][19][20][21] . We additionally examined buprenorphine receipt frequency on average over the course of the first 6 months.…”
Section: Data Extraction and Definitionsmentioning
confidence: 99%
“…Opioid agonist treatment is the recommended evidence-based treatment for opioid use disorder, considered to be the gold standard of care (Moss et al, 2018;Klimas et al, 2021;Hagedorn et al, 2018). OAT involves the daily prescription of full methadone agonists, such as methadone, or partial opioid agonists, such as buprenorphine/naloxone, to reduce opioid use, cravings, withdrawal symptoms, and overdose (Moss et al, 2018).…”
Section: Opioid Use Disorder and Opioid Agonist Treatmentmentioning
confidence: 99%